Park Avenue Securities LLC Acquires 3,081 Shares of Insmed Incorporated (NASDAQ:INSM)

Park Avenue Securities LLC lifted its holdings in Insmed Incorporated (NASDAQ:INSM) by 38.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,036 shares of the biopharmaceutical company’s stock after purchasing an additional 3,081 shares during the period. Park Avenue Securities LLC’s holdings in Insmed were worth $842,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Elequin Capital LP bought a new position in shares of Insmed in the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC increased its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC increased its stake in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the period. NBC Securities Inc. bought a new position in shares of Insmed in the first quarter worth about $49,000. Finally, Versant Capital Management Inc increased its stake in shares of Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 590 shares during the period.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of recent analyst reports. Jefferies Financial Group reiterated a “buy” rating on shares of Insmed in a research note on Tuesday. Citigroup upgraded Insmed to a “buy” rating in a research note on Tuesday. Wells Fargo & Company boosted their price target on Insmed from $107.00 to $119.00 and gave the company an “overweight” rating in a research note on Wednesday. Royal Bank of Canada boosted their price target on Insmed from $99.00 to $106.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Leerink Partners boosted their price target on Insmed from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.81.

Insmed Stock Down 1.1%

NASDAQ INSM opened at $96.88 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock’s 50 day moving average is $70.73 and its two-hundred day moving average is $73.47. The company has a market capitalization of $17.65 billion, a price-to-earnings ratio of -17.33 and a beta of 0.80. Insmed Incorporated has a 1-year low of $60.40 and a 1-year high of $100.00.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.06) earnings per share. Equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, insider Michael Alexander Smith sold 4,407 shares of the business’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $67.81, for a total value of $298,838.67. Following the transaction, the insider now directly owns 92,203 shares of the company’s stock, valued at $6,252,285.43. The trade was a 4.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the transaction, the insider now directly owns 89,407 shares in the company, valued at $8,352,401.94. The trade was a 52.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 262,166 shares of company stock valued at $20,585,587. 3.00% of the stock is currently owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.